New radiation rhythm may outsmart glioblastoma and save memory
NCT ID NCT07452458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase III trial tests a new way to deliver radiation called TMPRT, which gives the total dose in short pulses with breaks in between, for people with a newly diagnosed, aggressive brain cancer (MGMT-unmethylated glioblastoma). About 398 adults will be randomly assigned to get either standard radiation or TMPRT, both with the chemotherapy drug temozolomide. The goal is to see if TMPRT helps people live longer and protects memory and thinking, which often decline after standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Temporally-modulated pulsed radiation therapy (TMPRT) and temozolomide
What this could lead to
If it works, this could offer a new radiation approach that extends survival and better preserves memory and thinking in people with a hard-to-treat glioblastoma.
What could go wrong
This is still an early-stage trial (not yet recruiting) and previous new therapies for this tumor type have failed. The benefit over standard care is uncertain, and radiation always carries risks like fatigue and brain swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.